Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

Core Viewpoint - Verve Therapeutics (VERV) has shown a significant price increase of 25.4% over the past four weeks, with a mean price target of $24.75 indicating a potential upside of 367.9% from its current price of $5.29 [1] Price Targets and Analyst Consensus - The average price target for VERV includes estimates ranging from a low of $15 to a high of $39, with a standard deviation of $7.81, indicating variability among analysts [2] - The lowest estimate suggests an increase of 183.6%, while the most optimistic estimate points to a 637.2% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about VERV's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher [11] - Over the last 30 days, five estimates have moved higher with no negative revisions, leading to a 9.6% increase in the Zacks Consensus Estimate [12] - VERV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]